Radius Health Reports Third Quarter 2014 Financial and

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Radius Health Reports Third Quarter 2014 Financial and Operating Results

WALTHAM, Mass., Nov. 10, 2014 (GLOBE NEWSWIRE) -- Radius Health, Inc. ("Radius") (Nasdaq: RDUS ), a science-driven biopharmaceutical company focused on developing new therapeutics for patients with osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers, reported its financial results for the third quarter ended September 30, 2014, and provided recent corporate highlights.

"We have continued to make significant progress in the third quarter of 2014," said Robert Ward, President and Chief Executive Officer of Radius Health. "Our Phase 3 study (ACTIVE) evaluating the investigational drug abaloparatide-SC, a synthetic peptide analog of parathyroid hormone-related protein for potential use in the reduction of fractures in postmenopausal osteoporosis has completed last patient, last visit, and we plan to announce the top-line 18-month fracture data in late December 2014. In addition, we successfully completed a follow-on public offering on October 7, 2014, and initiated a Phase 1 maximum tolerated dose, or MTD, study of the investigational drug RAD1901, a selective estrogen receptor degrader, or SERD. The Phase 1 MTD study is designed to evaluate the tolerability, safety and pharmacokinetics of RAD1901 and to provide a pharmacodynamic assessment of estrogen receptor turnover following administration of RAD1901 using 18F-estradiol positron emission tomography, or FES-PET, imaging."

Recent Corporate Highlights

Additional Public Offering

On October 7, 2014, Radius completed an additional public offering whereby it sold 2,750,000 shares of common stock at a price of $18.25 per share, for aggregate proceeds, net of underwriting discounts, commissions, and estimated offering costs, of approximately $46.9 million. The underwriters purchased an additional 378,524 shares by exercising a portion of the over-allotment option granted to them in connection with the offering. As a result of the public offering and subsequent exercise of the over-allotment option, Radius received aggregate proceeds, net of underwriting discounts, commissions, and estimated offering costs of approximately $53.3 million, which will primarily be used to fund the continued development of RAD1901, development of our other product candidates, and other general corporate purposes.

Investigational Drug Abaloparatide-SC

The last patient, last visit for the 18-month anabolic treatment portion of the Phase 3 clinical trial occurred during October 2014 and all continuing patients are now enrolled in the 6-month standard-of-care extension study. Radius plans to announce the top-line fracture data, including efficacy and safety data for each treatment group included in the 18-month anabolic phase, in late December 2014. Radius will remain blinded at the patient and site level until such time as the 6-month standard-of-care extension study is completed.

If the results demonstrate that abaloparatide-SC met the study endpoints, Radius plans to use the results from this Phase 3 clinical trial to support the submission of a new drug application ("NDA") to the U.S. Food and Drug Administration ("FDA") and a Marketing Authorization Application ("MAA") to the European Medicines Agency in mid-2015. Radius plans on providing more detail regarding the expected timing of completion of the 6-month standard-of-care extension study and subsequent submission of both an NDA and MAA in its late December 2014 announcement.

The abaloparatide-SC Phase 2 clinical study manuscript entitled "Effects of Abaloparatide, a Human Parathyroid Hormone-related Peptide Analog, on Bone Mineral Density in Postmenopausal Women with Osteoporosis", has been accepted for publication in the Journal of Clinical Endocrinology and Metabolism. Radius expects the publication will be available online in November 2014.

Investigational Drug RAD1901

In June 2014, Radius initiated a Phase 1 MTD study in healthy volunteers for another potential lead product candidate, investigational drug RAD1901. At higher doses, RAD1901 is being developed for the potential treatment of metastatic breast cancer. The Phase 1 study was designed to evaluate the tolerability, safety and pharmacokinetics of RAD1901, and used FES-PET imaging to provide a pharmacodynamic assessment of estrogen receptor turnover following administration. As of September 30, 2014, 40 subjects had completed dose escalation in the ongoing MTD study, and FES-PET imaging had been completed in a total of six subjects across two different doses. The data indicate that each of these six subjects demonstrated, based upon FES-PET imaging, suppression of the FES-PET signal to background levels after six days of dosing. In addition, RAD1901, at the doses that showed the suppression of the FES-PET signal, was well tolerated in these six patients. Radius plans to commence a Phase 1b clinical study of RAD1901 for metastatic breast cancer in late 2014.

At low doses, RAD1901 acts as a selective estrogen-receptor modulator ("SERM"). Low-dose RAD1901 has shown potential to be effective for the treatment of vasomotor symptoms such as hot flashes in a successful Phase 2 proof of concept study. Radius intends to commence a Phase 2b clinical trial in vasomotor symptoms in the second half of 2015.

Anticipated Upcoming Milestones

Radius expects the following upcoming milestones and presentations:

  • Investigational Drug Abaloparatide-SC
    • Report top-line 18-month fracture data from the abaloparatide-SC Phase 3 clinical study in late December 2014.
    • Submit a NDA and an MAA for abaloparatide-SC in mid-2015 if the results of the study are favorable
  • Investigational Drug RAD1901
    • Commence a Phase 1b clinical study of RAD1901 in metastatic breast cancer in late 2014.
    • Present RAD1901 data at the San Antonio Breast Cancer Symposium in December 2014.
    • Commence a Phase 2b clinical study of RAD1901 for the potential treatment of vasomotor symptoms in the second half of 2015
  • Presentations
    • Therapeutic Area Partnerships (November 2014), where the investigational drug RAD1901 has been selected by the meeting organizers (an industry speaker board and publishers of In Vivo, Startup and The Pink Sheet) as one of the "Top Oncology Projects to Watch".
    • Jefferies 2014 Global Healthcare Conference (November 2014).

Third Quarter 2014 Financial Results

For the three months ended September 30, 2014, Radius reported a net loss of $17.4 million, or $0.59 per share, as compared to a net loss of $20.3 million, or $65.05 per share for the three months ended September 30, 2013. The net loss per share calculation for the three months ended September 30, 2014 includes the impact of Radius' convertible preferred stock converting into common stock upon the completion of its initial public offering in June 2014. The decrease in net loss for the 2014 period as compared to the 2013 period was primarily due to a decrease in research and development expenses and other (expense) income, net, partially offset by an increase in general and administrative expenses.

Research and development expenses for the three months ended September 30, 2014 were $13.8 million, compared to $15.5 million for the same period in 2013. The decrease for the 2014 period as compared to the 2013 period was primarily attributable to a decrease in the costs associated with the abaloparatide-SC Phase 3 clinical trial as it nears completion, and a decrease in the costs incurred for the development of the investigational drug abaloparatide-TD, for which a Phase 2 clinical trial was completed in September 2013. These reductions in cost were partially offset by an increase in the costs associated with the advancement of RAD1901.

For the three months ended September 30, 2014, there was zero other (expense) income, net, as compared to $2.6 million other (expense) income, net for the same period in 2013. Other (expense) income, net has historically reflected changes in the fair value of Radius' stock liability, other liability and warrant liability.

General and Administrative expenses for the three months ended September 30, 2014 were $2.8 million, compared to $1.6 million for the same period in 2013. The increase for the 2014 period as compared to the 2013 period was primarily attributable to higher legal fees and consulting support costs, as well as higher compensation costs, including non-cash stock-based compensation expense, due to an overall increase in employee headcount.

As of September 30, 2014, Radius had $68.5 million in cash, cash equivalents and marketable securities.

Conference Call and Webcast

Radius will host a conference call tomorrow at 8:00 a.m. EST to discuss its third quarter results ended September 30, 2014 and to provide a corporate update.

The live call may be accessed by dialing 1-877-705-6003 for domestic callers or 1-201-493-6725 for international callers. A live webcast of the conference call will be available online from the investor section of Radius' website at www.radiuspharm.com and will be available for replay following the call for 30 days. The full text of the announcement and financial results will also be available on Radius' website.

About Radius Health

Radius is a science-driven biopharmaceutical company developing new therapeutics for patients with advanced osteoporosis as well as other serious endocrine-mediated diseases, including hormone responsive cancers. Radius' lead development candidate is the investigational drug, abaloparatide (BA058) for subcutaneous injection, currently in Phase 3 development for the potential use in the reduction of fracture risk in postmenopausal women with severe osteoporosis. The Radius clinical portfolio also includes an investigational abaloparatide transdermal patch for osteoporosis and the investigational drug, RAD1901, for the potential treatment of hormone driven, or hormone resistant, metastatic breast cancer. www.radiuspharm.com

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding the benefits of RAD1901, expectations regarding clinical trials, expectations regarding abaloparatide-SC and RAD1901 in the regulatory process with the U.S. Food and Drug Administration and upcoming events and presentations, and each of the statements in the section titled "Anticipated Upcoming Milestones".

These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: we have no product revenues; our need for additional funding, which may not be available; we are not currently profitable and may never become profitable; restrictions imposed on our business by our credit facility, and risks related to default on our obligations under our credit facility; risks related to raising additional capital; our limited operating history; quarterly fluctuation in our financial results; our dependence on the success of abaloparatide-SC, and our inability to ensure that abaloparatide-SC will obtain regulatory approval or be successfully commercialized; risks related to clinical trials, including having most of our products in early stage clinical trials and uncertainty that results will support our product candidate claims; the risk that adverse side effects will be identified during the development of our product candidates; product candidates for which we obtain marketing approval, if any, could be subject to restrictions or withdrawal from the market and we may be subject to penalties; failure to achieve market acceptance of our product candidates; risks related to the use of our limited resources on particular product candidates and not others; delays in enrollment of patients in our clinical trials, which could delay or prevent regulatory approvals; the dependence of our drug development program upon third-parties who are outside our control; the risk that a regulatory or government official will determine that third-parties with a financial interest in the outcome of the Phase 3 study of abaloparatide-SC affected the reliability of the data from the study; our reliance on third parties to formulate and manufacture our product candidates; failure to establish additional collaborations; our lack of experience selling, marketing and distributing products and our lack of internal capability to do so; failure to compete successfully against other drug companies; developments by competitors may render our products or technologies obsolete or non-competitive; risks related to the fact that our drugs may sell for inadequate prices or patients may be unable to obtain adequate reimbursement; effects of product liability lawsuits on commercialization of our products; failure to comply with obligations of our intellectual property licenses; failure to protect our intellectual property or failure to secure necessary intellectual property related to abaloparatide-SC, abaloparatide-TD, RAD1901 and/or RAD140; our or our licensors' inability to obtain and maintain patent protection for technology and products; risks related to our compliance and our licensors' compliance with patent application requirements; failure to protect the confidentiality of our trade secrets; risks related to our infringement of third parties' rights; risks associated with intellectual property litigation, including expending substantial resources and distracting personnel from their normal responsibilities; risks related to employees' disclosure of former employers' trade secrets; risks associated with healthcare reform; our failure to comply with healthcare laws and regulations; our exposure to claims associated with the use of hazardous materials and chemicals; inability to successfully manage our growth; risks relating to business combinations and acquisitions; our reliance on key executive officers and advisors; our inability to hire additional qualified personnel; volatility in the price of our common stock; capital appreciation is the only source of gain for our common stock; risks related to increased costs and compliance initiatives associated with operating as a public company; our directors, executive officers and principal stockholders have substantial control over us and could delay or prevent a change in control; future sales of our common stock could depress the price of our common stock; inaccurate or unfavorable information about us could cause the price of our common stock to decline; provisions in our charter documents and Delaware law could discourage takeover attempts; and our ability to use our net operating loss carryforwards and certain other tax attributes may be limited. These and other important factors discussed under the caption "Risk Factors" in our Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission, or SEC, on November 10, 2014, and our other reports filed with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release.

Condensed Balance Sheets    
 (Amounts in thousands)    
     
  September 30, December 31, 
  2014 2013
  (unaudited)  
ASSETS    
Current assets:    
Cash and cash equivalents  $ 16,466  $ 12,303
Marketable securities  52,048  -- 
Prepaid expenses and other current assets  1,380  334
Total current assets  69,894  12,637
Property and equipment, net  790  76
Other assets  252  45
Total assets  $ 70,936  $ 12,758
     
LIABILITIES, CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (DEFICIT)    
Current liabilities:    
Accounts payable  $ 1,309  $ 300
Accrued expenses and other current liabilities  21,911  22,007
Current portion of note payable, net of discount  2,027  13,005
Total current liabilities  25,247  35,312
     
Note payable, net of current portion and discount  22,295  -- 
Warrant liability  --   1,945
Convertible preferred stock    252,802
Common stock, $.0001 par value; 200,000,000 shares and 100,000,000 shares authorized, 29,747,797 shares and 385,664 shares issued and outstanding at September 30, 2014 and December 31, 2013, respectively  3  -- 
Additional paid-in-capital  349,677  -- 
Accumulated other comprehensive loss  (10)  
Accumulated deficit  (326,276)  (277,301)
Total stockholders' equity (deficit)  23,394  (277,301)
Total liabilities, convertible preferred stock and stockholders' equity (deficit)  $ 70,936  $ 12,758
         
         
         
Condensed Statements of Operations and Comprehensive Loss        
(Unaudited)        
(Amounts in thousands, except share and per share amounts)        
         
  Three Months Ended Nine Months Ended
  September 30, September 30,
  2014 2013 2014 2013
         
OPERATING EXPENSES:        
Research and development $ 13,817 $ 15,543 $ 34,152 $ 49,070
General and administrative 2,836 1,621 8,045 4,643
Loss from operations (16,653) (17,164) (42,197) (53,713)
OTHER (EXPENSE) INCOME:        
Other (expense) income, net -- (2,607) (506) 7,465
Loss on retirement of note payable -- -- (203) --
Interest income 35 11 42 27
Interest expense (802) (582) (1,653) (1,938)
NET LOSS $ (17,420) $ (20,342) $ (44,517) $ (48,159)
OTHER COMPREHENSIVE LOSS, NET OF TAX:        
Unrealized loss from marketable securities (11) (3) (10) --
COMPREHENSIVE LOSS $ (17,431) $ (20,345) $ (44,527) $ (48,159)
LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS - BASIC AND DILUTED (Note 11): $ (17,420) $ (25,090) $ (53,517) $ (60,857)
LOSS PER SHARE:        
Basic $ (0.59) $ (65.05) $ (4.23) $ (159.09)
Diluted $ (0.59) $ (65.05) $ (4.23) $ (159.09)
WEIGHTED AVERAGE SHARES:        
Basic 29,746,426 385,688 12,651,628 382,541
Diluted 29,746,426 385,688 12,651,628 382,541

Investor Relations Barbara Ryan FTI Consulting Managing Director 212-850-5679 Media Relations Kimberly Ha FTI Consulting Senior Director 212-850-5612

Scroll down for more posts ▼

Top 10 Most Recent News Articles

MetaComp Targets ASEAN's Cross-Border Payment Snarl

Updated Category News Views 70

ASEAN payment plumbing is still a patchwork, and MetaComp is betting that patchwork has finally become painful enough to fix. The Singapore-based payments firm says its StableX Agentic Network has topped 1,000 members and reaches more than 100,000 users in its first year. That is a respectable early footprint, not a victory lap. Cross-border payments are littered with...

Continue Reading
Nightguards and TMJ Appliances Require Different Calls

Updated Category News Views 72

Two clear plastic devices can invite a costly wrong turn. Dr. Terrance O’Keefe’s explanation, published Nov. 18, 2026, draws a line that patients too often blur: a nightguard protects teeth from grinding, while a TMJ appliance is meant to address joint and muscle strain tied to temporomandibular disorders. They may look alike sitting in a case. Their jobs are not...

Continue Reading
Century's Florence Model Openings Put Arizona in Focus

Updated Category News Views 18

Six furnished houses in Florence may sound like a modest ribbon-cutting, but homebuilding is a business of small field signals before the quarterly numbers ever show up. Century Communities is scheduled to host a November grand opening for six model homes spanning two new communities in Florence, Arizona. For investors tracking NYSE:CCS, that is not a thesis by itself. It...

Continue Reading
My Home Delivery's Bold Move in Big & Bulky Sector

Updated Category News Views 304

Redefining Big & Bulky Deliveries with AI Let me tell you, the logistics world isn't for the timid, and My Home Delivery (MHD) is swinging for the fences with their latest tech platform. These folks are rolling out an AI-driven system that promises to turn the bulky goods market on its head. Imagine moving your brand new fridge or that king-size bed across town without...

Continue Reading
Boat Market Forecast Puts Services in the Driver’s Seat

Updated Category News Views 51

A jet ski is not exactly a sober economic indicator, yet the water is telling a useful story. MarketsandMarkets projects the global recreational boat market will rise from $31.38 billion in 2026 to $48.06 billion in 2033, a 6.3% compound annual growth rate. That is respectable growth for a costly discretionary category that got knocked around by softer purchasing activity...

Continue Reading
Excel Treatment Center Adds ART Trauma Therapy Option

Updated Category News Views 61

Trauma rarely arrives at an addiction program wearing a name tag. Excel Treatment Center in Dover, New Jersey, is responding to that uncomfortable reality by adding Accelerated Resolution Therapy® (ART) to the individual, group, and family therapy already available to its clients. The center says its therapists have completed ART training, and the approach is now part of...

Continue Reading
VisionX AI Bets on Graphs to Track Crypto Crime Nets

Updated Category News Views 91

Money laundering rarely travels in a straight line, and that is precisely the sore spot VisionX AI is trying to jab. The Singapore-based RegTech company has introduced AEGIS, a proprietary Large Graph Model built around financial-crime networks, alongside TraceX, a blockchain investigation platform meant to turn that network view into usable leads. It is a sensible...

Continue Reading
Hanon's BMW Thermal Win Matters Beyond the Trophy Case Today

Updated Category News Views 116

A 16-Kilogram Box Just Grabbed the Auto Supply Chain’s Attention Hanon Systems did not win these two 2026 PACE honors by polishing up some old hose-and-valve package. Its Highly Integrated Cooling Entity, or HICE, is aimed right at a stubborn electric-vehicle problem: keeping a vehicle’s thermal systems controlled without turning the architecture into a sprawling,...

Continue Reading
Watson Motion Tests Military Pretrial Confinement Rules

Updated Category News Views 60

Military confinement fights are rarely neat, and this one comes with a short clock but plenty of unanswered questions. Defense lawyers for U.S. Air Force Maj. Jason Watson argued on Nov. 17 that he should be released from pretrial confinement while his case proceeds. A military judge is ordinarily expected to issue a ruling within 14 days of the hearing, under the court's...

Continue Reading
Paratus on the Move: Seagems JV Under the Microscope

Updated Category News Views 248

What's Cooking with Paratus Energy? Paratus Energy Services Ltd. (ticker: PLSV) just threw us a curveball, announcing a strategic review of its participation in the Seagems joint venture. Now, before you get too jazzed about ticker talk—hold your horses. No one's making any promises about transactions just yet. The decision's still hanging in the balance, even as they...

Continue Reading

Top 5 Most Recently Viewed Articles

Mastering the Market: A Beginner's Guide to Stock Futures

Updated Category Markets Views 372

Introduction to Stock Futures A stock future is a kind of financial agreement that obligates the purchaser to buy, and the dealer to sell, a certain quantity of shares at a preset price on a specified future day. This sector of the finance market is very important for many players such as investors, daily traders, and financial analysts. Learning about stock futures can...

Continue Reading
Q2's New CFO, Jonathan Price, Steps into Key Role

Updated Category News Views 248

Q2 Holdings Welcomes a New Chief Financial Officer Q2 Holdings, Inc. (NYSE:QTWO), a leader in delivering digital transformation solutions for the financial services sector, has announced the noteworthy appointment of Jonathan A. Price as its new Chief Financial Officer. This strategic change is poised to take effect soon, marking an exciting chapter for the company. A...

Continue Reading
Metro-North Settlement of Over $182 Million Marks Legal Milestone

Updated Category News Views 138

Landmark Settlement in Metro-North Train Crash Case A recently published article in the New York Law Journal sheds light on a groundbreaking settlement of over $182 million related to one of the deadliest events in Metro-North Railroad history. This settlement, stemming from the tragic crash that resulted in the loss of five lives and injured many others, represents a...

Continue Reading
Advocacy for Injured Workers: A Call to Action at WSIB

Updated Category News Views 176

Injured Workers Rally for Change at the WSIB In a significant show of solidarity, injured workers, along with supporters, are uniting to demand improved conditions and benefits from the Workplace Safety Insurance Board (WSIB). This rally is not just about protest; it aims to highlight the dire circumstances faced by families of injured workers as students return to...

Continue Reading
eQ Plc Updates on Managerial Transactions and Business Growth

Updated Category News Views 282

eQ Plc's Recent Managerial Transactions eQ Plc recently provided vital updates regarding transactions involving key managerial figures. These notifications enhance the transparency of operations within the company. Key Individuals Involved Rettig Oy Ab is a notable entity associated with eQ Plc, and significant figures within this relationship include Tomas von Rettig and...

Continue Reading